Tag: osteoarthritis

April 26, 2018

Axsome Therapeutics Announces Interim Analysis of STRIDE-1 Trial

Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3.
April 19, 2018

Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA

Flexion Therapeutics (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone...
April 9, 2018

CBD​ ​is​ ​Improving​ ​Health​ ​and​ ​Driving​ ​the​ ​Cannabis​ ​Industry

CBD​ ​is​ ​improving​ ​health​ ​and​ driving​ ​the​ ​cannabis​ ​industry. Know more about its health benefits and opportunities for CBD-based companies.
March 20, 2018

Antibe Therapeutics’ Share Price Soars with Positive Phase 2B Results

The company has released positive Phase 2B clinical trial results for its lead drug. The study was to evaluate the...
March 16, 2018

Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin

Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies...
June 21, 2017

U.S. Stem Cell's Chief Science Officer Co-Authors Featured Paper

A paper co-authored by Kristin Comella's, chief science officer for U.S. Stem Cell about an intra-articular injection for the treatment...
April 7, 2017

Flexion Appoints New Chief Medical Officer

Flexion Therapeutics (NASDAQ: FLXN) appointed Dr. Yamo Deniz as its new Chief Medical Officer.